Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Targeting the epigenome for treatment of cancer

Oncogene volume 31, pages 3827–3844 (2012)Cite this article

Subjects

Abstract

Cancer genome analyses have revealed that the enzymes involved in epigenetic gene regulation are frequently deregulated in cancer. Here we describe the enzymes that control the epigenetic state of the cell, how they are affected in cancer and how this knowledge can be exploited to treat cancer with a new arsenal of selective therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J et al. (2009). The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171–1176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D et al. (2010). An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2: 54ra77.

    PubMed  PubMed Central  Google Scholar 

  • Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY et al. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965–968.

    CAS  PubMed  Google Scholar 

  • Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J et al. (2007). Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109: 713–717.

    CAS  PubMed  Google Scholar 

  • Arif M, Vedamurthy BM, Choudhari R, Ostwal YB, Mantelingu K, Kodaganur GS et al. (2010). Nitric oxide-mediated histone hyperacetylation in oral cancer: target for a water-soluble HAT inhibitor, CTK7A. Chem Biol 17: 903–913.

    CAS  PubMed  Google Scholar 

  • Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E . (2005). Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75: 252–257.

    CAS  PubMed  Google Scholar 

  • Ayton PM, Cleary ML . (2003). Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298–2307.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Baek SH . (2011). When signaling kinases meet histones and histone modifiers in the nucleus. Mol Cell 42: 274–284.

    CAS  PubMed  Google Scholar 

  • Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D et al. (2007). CHD5 is a tumor suppressor at human 1p36. Cell 128: 459–475.

    CAS  PubMed  Google Scholar 

  • Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ . (2008). A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22: 1026–1034.

    CAS  PubMed  Google Scholar 

  • Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK . (2003). Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278: 19134–19140.

    CAS  PubMed  Google Scholar 

  • Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM et al. (2011). Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29: 255–265.

    CAS  PubMed  Google Scholar 

  • Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenfuhr M et al. (2009). Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23: 1177–1182.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S et al. (2001). BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61: 2409–2412.

    CAS  PubMed  Google Scholar 

  • Bedford MT, Clarke SG . (2009). Protein arginine methylation in mammals: who, what, and why. Mol Cell 33: 1–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R et al. (2009). Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA 106: 21830–21835.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. (2011). MLL-rearranged leukemia is dependent on Aberrant H3K79 Methylation by DOT1L. Cancer Cell 20: 66–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S et al. (2010). Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18: 436–447.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Biegel JA, Fogelgren B, Wainwright LM, Zhou JY, Bevan H, Rorke LB . (2000a). Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosomes Cancer 28: 31–37.

    CAS  PubMed  Google Scholar 

  • Biegel JA, Fogelgren B, Zhou JY, James CD, Janss AJ, Allen JC et al. (2000b). Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res 6: 2759–2763.

    CAS  PubMed  Google Scholar 

  • Biegel JA, Kalpana G, Knudsen ES, Packer RJ, Roberts CW, Thiele CJ et al. (2002). The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62: 323–328.

    CAS  PubMed  Google Scholar 

  • Biegel JA, Pollack IF . (2004). Molecular analysis of pediatric brain tumors. Curr Oncol Rep 6: 445–452.

    PubMed  Google Scholar 

  • Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S et al. (2009). Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147: 507–514.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. (2007). Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25: 3884–3891.

    Article  CAS  PubMed  Google Scholar 

  • Bolden JE, Peart MJ, Johnstone RW . (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784.

    CAS  PubMed  Google Scholar 

  • Boumber Y, Issa JP . (2011). Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220–226, 228.

    Google Scholar 

  • Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC et al. (2009). Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115: 5541–5549.

    CAS  PubMed  Google Scholar 

  • Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. (2010). Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6: 238–243.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P et al. (2008). Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14: 6296–6301.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P et al. (2005). Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65: 6305–6311.

    CAS  PubMed  Google Scholar 

  • Bultman S, Gebuhr T, Yee D, La Mantia C, Nicholson J, Gilliam A et al. (2000). A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 6: 1287–1295.

    CAS  PubMed  Google Scholar 

  • Bultman SJ, Herschkowitz JI, Godfrey V, Gebuhr TC, Yaniv M, Perou CM et al. (2008). Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27: 460–468.

    CAS  PubMed  Google Scholar 

  • Buszczak M, Paterno S, Spradling AC . (2009). Drosophila stem cells share a common requirement for the histone H2B ubiquitin protease scrawny. Science 323: 248–251.

    CAS  PubMed  Google Scholar 

  • Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103–107.

    CAS  PubMed  Google Scholar 

  • Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V et al. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471: 513–517.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chadwick RB, Jiang GL, Bennington GA, Yuan B, Johnson CK, Stevens MW et al. (2000). Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci USA 97: 2662–2667.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chang Y, Zhang X, Horton JR, Upadhyay AK, Spannhoff A, Liu J et al. (2009). Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 16: 312–317.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chase A, Cross NC . (2011). Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613–2618.

    CAS  PubMed  Google Scholar 

  • Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L et al. (1997). Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90: 569–580.

    CAS  PubMed  Google Scholar 

  • Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G et al. (2010). H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 70: 7830–7840.

    CAS  PubMed  Google Scholar 

  • Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX et al. (2009). Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 106: 13433–13438.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE et al. (2003). Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399–409.

    CAS  PubMed  Google Scholar 

  • Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ et al. (2001). Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300–1304.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834–840.

    CAS  PubMed  Google Scholar 

  • Clapier CR, Cairns BR . (2009). The biology of chromatin remodeling complexes. Annu Rev Biochem 78: 273–304.

    CAS  PubMed  Google Scholar 

  • Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T et al. (2006). The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442: 307–311.

    CAS  PubMed  Google Scholar 

  • Coste A, Antal MC, Chan S, Kastner P, Mark M, O'Malley BW et al. (2006). Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J 25: 2453–2464.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H et al. (2008). Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19: 964–969.

    CAS  PubMed  Google Scholar 

  • Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. (2011). Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360–363.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P et al. (2009). A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 69: 4277–4285.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR et al. (2009). JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819–822.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. (2009). Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289–2301.

    PubMed  Google Scholar 

  • Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904–917.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T et al. (2009). Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 147: 97–101.

    CAS  PubMed  Google Scholar 

  • Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M et al. (2002). Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079–1082.

    CAS  PubMed  Google Scholar 

  • Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H et al. (2010). BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 12: 380–389.

    CAS  PubMed  Google Scholar 

  • Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB et al. (1994). Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 8: 869–884.

    CAS  PubMed  Google Scholar 

  • Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, Radlwimmer B et al. (2006). Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208: 554–563.

    CAS  PubMed  Google Scholar 

  • Eliazer S, Shalaby NA, Buszczak M . (2011). Loss of lysine-specific demethylase 1 nonautonomously causes stem cell tumors in the Drosophila ovary. Proc Natl Acad Sci USA 108: 7064–7069.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eliseeva ED, Valkov V, Jung M, Jung MO . (2007). Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 6: 2391–2398.

    CAS  PubMed  Google Scholar 

  • Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R . (2005). The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122: 835–847.

    CAS  PubMed  Google Scholar 

  • Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB et al. (1999). hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155: 1767–1772.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG et al. (2011). Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 3: 75ra25.

    PubMed  PubMed Central  Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223–232.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. (2010). Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28: 562–569.

    CAS  PubMed  Google Scholar 

  • Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK . (2008). Epigenetic reprogramming by adenovirus e1a. Science 321: 1086–1088.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. (2010). Selective inhibition of BET bromodomains. Nature 468: 1067–1073.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. (2009). Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733–2743.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Frescas D, Guardavaccaro D, Kuchay SM, Kato H, Poleshko A, Basrur V et al. (2008). KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle 7: 3539–3547.

    CAS  PubMed  Google Scholar 

  • Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V et al. (2008). CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100: 940–949.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A et al. (2004). Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10: 4314–4324.

    CAS  PubMed  Google Scholar 

  • Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS et al. (2009). Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27: 2052–2058.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al. (2006). Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108: 3271–3279.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR . (2007). An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449: 1073–1077.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Geutjes EJ, Tian S, Roepman P, Bernards R . (2011). Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res Treat (http://www.ncbi.nlm.nih.gov/pubmed/21465168).

  • Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A et al. (2011). Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 29: 2052–2059.

    PubMed  PubMed Central  Google Scholar 

  • Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S et al. (2004). Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361–371.

    CAS  PubMed  Google Scholar 

  • Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D . (2007). The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 26: 7058–7066.

    CAS  PubMed  Google Scholar 

  • Glaros S, Cirrincione GM, Palanca A, Metzger D, Reisman D . (2008). Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 68: 3689–3696.

    CAS  PubMed  Google Scholar 

  • Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. (2006). Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361–6369.

    CAS  PubMed  Google Scholar 

  • Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L et al. (2007). Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448: 1063–1067.

    CAS  PubMed  Google Scholar 

  • Grand F, Kulkarni S, Chase A, Goldman JM, Gordon M, Cross NC . (1999). Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res 59: 3870–3874.

    CAS  PubMed  Google Scholar 

  • Griffiths DS, Li J, Dawson MA, Trotter MW, Cheng YH, Smith AM et al. (2011). LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol 13: 13–21.

    CAS  PubMed  Google Scholar 

  • Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S et al. (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875–878.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN . (2009a). Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA 106: 7751–7755.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Haberland M, Montgomery RL, Olson EN . (2009b). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN . (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177–189.

    CAS  PubMed  Google Scholar 

  • Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I et al. (2010). Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J Med Chem 53: 5629–5638.

    CAS  PubMed  Google Scholar 

  • Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F et al. (2008). Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 18: 274–278.

    CAS  PubMed  Google Scholar 

  • He L, Yu JX, Liu L, Buyse IM, Wang MS, Yang QC et al. (1998). RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2–M cell cycle arrest and/or apoptosis. Cancer Res 58: 4238–4244.

    CAS  PubMed  Google Scholar 

  • Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, Kao CF et al. (2003). Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 17: 2648–2663.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102: 8567–8572.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T et al. (2010). G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem 285: 9636–9641.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM et al. (2007). Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 104: 8023–8028.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B et al. (2009). Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 15: 7217–7228.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE . (2011). Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat (http://www.ncbi.nlm.nih.gov/pubmed/21452019).

  • Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S et al. (2005). Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23: 3948–3956.

    CAS  PubMed  Google Scholar 

  • Issa JP, Kantarjian HM . (2009). Targeting DNA methylation. Clin Cancer Res 15: 3938–3946.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y . (2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466: 1129–1133.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L et al. (2009). Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res 15: 1923–1930.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M . (1999). Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13: 2678–2690.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K et al. (2001). A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98: 1264–1267.

    CAS  PubMed  Google Scholar 

  • Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L et al. (2008). DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13: 529–541.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH et al. (2008). Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 19: 185–190.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R et al. (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228–231.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P et al. (2007). Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 449: 1068–1072.

    CAS  PubMed  Google Scholar 

  • Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R et al. (2006). Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66: 11341–11347.

    CAS  PubMed  Google Scholar 

  • Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. (2005). Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604–3608.

    CAS  PubMed  Google Scholar 

  • Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794–1803.

    CAS  PubMed  Google Scholar 

  • Kelly TK, De Carvalho DD, Jones PA . (2010). Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069–1078.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kilpivaara O, Levine RL . (2008). JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22: 1813–1817.

    CAS  PubMed  Google Scholar 

  • Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V et al. (2011). Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29: 1198–1203.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M . (2001a). Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J 20: 7184–7196.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N et al. (2001b). Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia 15: 89–94.

    CAS  PubMed  Google Scholar 

  • Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606–11611.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Klochendler-Yeivin A, Fiette L, Barra J, Muchardt C, Babinet C, Yaniv M . (2000). The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1: 500–506.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al. (2006). A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108: 3262–3270.

    CAS  PubMed  Google Scholar 

  • Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468: 839–843.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR et al. (2008). Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One 3: e2037.

    PubMed  PubMed Central  Google Scholar 

  • Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H et al. (2001). Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 98: 6348–6353.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML et al. (2007). Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25: 473–481.

    CAS  PubMed  Google Scholar 

  • Kuck D, Caulfield T, Lyko F, Medina-Franco JL . (2010). Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 9: 3015–3023.

    CAS  PubMed  Google Scholar 

  • Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM et al. (2000). Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14: 272–277.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T et al. (2002). Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30: 365–366.

    CAS  PubMed  Google Scholar 

  • Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT . (2009). The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 116: 225–237.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lane AA, Chabner BA . (2009). Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459–5468.

    CAS  PubMed  Google Scholar 

  • Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. (2009). Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41: 838–842.

    CAS  PubMed  Google Scholar 

  • Lavau C, Du C, Thirman M, Zeleznik-Le N . (2000). Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 19: 4655–4664.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW et al. (2008). Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105: 16224–16229.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T et al. (2008). The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68: 7561–7569.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. (2010). DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424–2433.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA et al. (2011). Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 43: 828–829.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R et al. (2010). Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31: 512–520.

    CAS  PubMed  Google Scholar 

  • Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP et al. (2009a). Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28: 4491–4500.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Liu H, Cheng EH, Hsieh JJ . (2009b). MLL fusions: pathways to leukemia. Cancer Biol Ther 8: 1204–1211.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S et al. (1999). A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically upregulated in breast cancer. J Biol Chem 274: 15633–15645.

    CAS  PubMed  Google Scholar 

  • Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J et al. (2008). A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14: 7138–7142.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R . (2007). FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252.

    CAS  PubMed  Google Scholar 

  • Marschalek R . (2011). Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 152: 141–154.

    CAS  PubMed  Google Scholar 

  • Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H . (2006). Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484–491.

    CAS  PubMed  Google Scholar 

  • McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W et al. (2008). Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 68: 5753–5759.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M . (2004). Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer 41: 170–177.

    CAS  PubMed  Google Scholar 

  • Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K et al. (2011). Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 117: 4869–4877.

    PubMed  Google Scholar 

  • Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH et al. (2005). LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436–439.

    CAS  PubMed  Google Scholar 

  • Miller CT, Moy JR, Lin L, Schipper M, Normolle D, Brenner DE et al. (2003). Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 9: 4819–4825.

    CAS  PubMed  Google Scholar 

  • Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK et al. (2009). DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579–1588.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Modesitt SC, Sill M, Hoffman JS, Bender DP . (2008). A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109: 182–186.

    CAS  PubMed  Google Scholar 

  • Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S et al. (2010). Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 21: 109–113.

    CAS  PubMed  Google Scholar 

  • Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181–185.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. (2011). Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298–303.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mulero-Navarro S, Esteller M . (2008). Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 3: 210–215.

    PubMed  Google Scholar 

  • Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. (2011). CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471: 235–239.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Namdar M, Perez G, Ngo L, Marks PA . (2010). Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 107: 20003–20008.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nguyen AT, Taranova O, He J, Zhang Y . (2011). DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117: 6912–6922.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nicassio F, Corrado N, Vissers JH, Areces LB, Bergink S, Marteijn JA et al. (2007). Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr Biol 17: 1972–1977.

    CAS  PubMed  Google Scholar 

  • Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ et al. (2011). Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117: 336–342.

    CAS  PubMed  Google Scholar 

  • Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M et al. (2011). The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31: 776–786.

    PubMed  PubMed Central  Google Scholar 

  • Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S et al. (2009). Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41: 465–472.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510–522.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nowell PC . (2002). Tumor progression: a brief historical perspective. Semin Cancer Biol 12: 261–266.

    CAS  PubMed  Google Scholar 

  • Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B et al. (2009). Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15: 91–99.

    CAS  PubMed  Google Scholar 

  • Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP . (2008). Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111: 2382–2384.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Otterson GA, Hodgson L, Pang H, Vokes EE . (2010). Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 5: 1644–1648.

    PubMed  PubMed Central  Google Scholar 

  • Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, Gobeil S et al. (2009). Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol Cell 36: 219–230.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. (2011). Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789–796.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC et al. (2011). The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435–439.

    CAS  PubMed  Google Scholar 

  • Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. (2011). Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471: 189–195.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pedersen MT, Helin K . (2010). Histone demethylases in development and disease. Trends Cell Biol 20: 662–671.

    CAS  PubMed  Google Scholar 

  • Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M et al. (1995). Rubinstein–Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348–351.

    CAS  PubMed  Google Scholar 

  • Piekarz RL, Bates SE . (2009). Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 15: 3918–3926.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al. (2009). Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410–5417.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Quintas-Cardama A, Santos FP, Garcia-Manero G . (2010). Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 7: 433–444.

    CAS  PubMed  Google Scholar 

  • Quintas-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S et al. (2008). A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22: 965–970.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. (2011). TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20: 25–38.

    CAS  PubMed  Google Scholar 

  • Rahman N . (2005). Mechanisms predisposing to childhood overgrowth and cancer. Curr Opin Genet Dev 15: 227–233.

    CAS  PubMed  Google Scholar 

  • Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M et al. (2009). Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4: 97–101.

    PubMed  PubMed Central  Google Scholar 

  • Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ . (2005). Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570–8576.

    CAS  PubMed  Google Scholar 

  • Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P et al. (2010). A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150: 446–455.

    CAS  PubMed  Google Scholar 

  • Reisman D, Glaros S, Thompson EA . (2009). The SWI/SNF complex and cancer. Oncogene 28: 1653–1668.

    CAS  PubMed  Google Scholar 

  • Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE . (2003). Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63: 560–566.

    CAS  PubMed  Google Scholar 

  • Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH . (2000). Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97: 13796–13800.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Roberts CW, Leroux MM, Fleming MD, Orkin SH . (2002). Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2: 415–425.

    CAS  PubMed  Google Scholar 

  • Rodriguez-Nieto S, Canada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F et al. (2010). Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum Mutat 32: E1999–E2017.

    PubMed  Google Scholar 

  • Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M et al. (2005). Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol 18: 1249–1257.

    CAS  PubMed  Google Scholar 

  • Rousseau-Merck MF, Versteege I, Legrand I, Couturier J, Mairal A, Delattre O et al. (1999). hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors. Cancer Res 59: 3152–3156.

    CAS  PubMed  Google Scholar 

  • Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I et al. (2005). Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105: 4445–4454.

    CAS  PubMed  Google Scholar 

  • Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G et al. (2010). Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18: 590–605.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S et al. (2005). Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24: 4531–4539.

    CAS  PubMed  Google Scholar 

  • Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K et al. (2000). Amplification and overexpression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 89: 217–223.

    CAS  PubMed  Google Scholar 

  • Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G et al. (2010). Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115: 1131–1136.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J et al. (2009). A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 94: 1375–1382.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF et al. (2008). Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 14: 188–198.

    CAS  PubMed  Google Scholar 

  • Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM et al. (2007). Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3: 1709–1723.

    CAS  PubMed  Google Scholar 

  • Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al. (2009). Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69: 2065–2071.

    CAS  PubMed  Google Scholar 

  • Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O . (1999). Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 65: 1342–1348.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY et al. (2005). Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis 113: 264–268.

    CAS  PubMed  Google Scholar 

  • Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR et al. (2007). Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5: 457–459.

    CAS  PubMed  Google Scholar 

  • Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA . (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 5: 57–60.

    CAS  PubMed  Google Scholar 

  • Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P et al. (2011). Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 17: 1582–1590.

    CAS  PubMed  Google Scholar 

  • Steele-Perkins G, Fang W, Yang XH, Van Gele M, Carling T, Gu J et al. (2001). Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 15: 2250–2262.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Steine EJ, Ehrich M, Bell GW, Raj A, Reddy S, van Oudenaarden A et al. (2011). Genes methylated by DNA methyltransferase 3b are similar in mouse intestine and human colon cancer. J Clin Invest 121: 1748–1752.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H et al. (2005). Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754–1758.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930–935.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ting AH, McGarvey KM, Baylin SB . (2006). The cancer epigenome—components and functional correlates. Genes Dev 20: 3215–3231.

    CAS  PubMed  Google Scholar 

  • Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP . (1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681–8686.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS et al. (2009). Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 4: 522–526.

    PubMed  PubMed Central  Google Scholar 

  • van der Knaap JA, Kozhevnikova E, Langenberg K, Moshkin YM, Verrijzer CP . (2010). Biosynthetic enzyme GMP synthetase cooperates with ubiquitin-specific protease 7 in transcriptional regulation of ecdysteroid target genes. Mol Cell Biol 30: 736–744.

    CAS  PubMed  Google Scholar 

  • van der Knaap JA, Kumar BR, Moshkin YM, Langenberg K, Krijgsveld J, Heck AJ et al. (2005). GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Mol Cell 17: 695–707.

    CAS  PubMed  Google Scholar 

  • van der Vlag J, Otte AP . (1999). Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474–478.

    CAS  PubMed  Google Scholar 

  • van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C et al. (2009). Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521–523.

    CAS  PubMed  PubMed Central  Google Scholar 

  • van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A . (1991). Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65: 737–752.

    CAS  PubMed  Google Scholar 

  • Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS et al. (2008). Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 26: 483–488.

    CAS  PubMed  Google Scholar 

  • Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624–629.

    CAS  PubMed  Google Scholar 

  • Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al. (2011). Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539–542.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V et al. (2011). A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 7: 566–574.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R et al. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203–206.

    CAS  PubMed  Google Scholar 

  • Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. (2010). Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871–874.

    CAS  PubMed  Google Scholar 

  • Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E et al. (2009). Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15: 5002–5007.

    CAS  PubMed  Google Scholar 

  • Wagner JM, Hackanson B, Lubbert M, Jung M . (2010). Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 1: 117–136.

    CAS  Google Scholar 

  • Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H et al. (2009a). Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 459: 847–851.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J et al. (2009b). The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 41: 125–129.

    CAS  PubMed  Google Scholar 

  • Wang JK, Tsai MC, Poulin G, Adler AS, Chen S, Liu H et al. The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev, (2010) 24: 327–332.

    PubMed  PubMed Central  Google Scholar 

  • Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G et al. (2011). The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765–769.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W et al. (2009c). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138: 660–672.

    CAS  PubMed  Google Scholar 

  • Wartman LD, Larson DE, Xiang Z, Ding L, Chen K, Lin L et al. (2011). Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest 121: 1445–1455.

    PubMed  PubMed Central  Google Scholar 

  • Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43: 442–446.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Weichert W . (2009). HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280: 168–176.

    CAS  PubMed  Google Scholar 

  • Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M et al. (2008a). Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139–148.

    CAS  PubMed  Google Scholar 

  • Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M et al. (2008b). Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 14: 1669–1677.

    CAS  PubMed  Google Scholar 

  • Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K et al. (2005). Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16: 349–353.

    CAS  PubMed  Google Scholar 

  • Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA et al. (2009). Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 27: 469–475.

    CAS  PubMed  Google Scholar 

  • Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M et al. (2010). Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28: 4485–4491.

    CAS  PubMed  Google Scholar 

  • Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al. (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532–1543.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M . (2008). Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leukemia Res 32: 587–591.

    CAS  Google Scholar 

  • Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548–13558.

    CAS  PubMed  Google Scholar 

  • Wilson BG, Roberts CW . (2011). SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481–492.

    CAS  PubMed  Google Scholar 

  • Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T et al. (2007). Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9: 347–353.

    CAS  PubMed  Google Scholar 

  • Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA et al. (2009). Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94: 164–170.

    CAS  PubMed  Google Scholar 

  • Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW . (2007). 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26: 77–90.

    CAS  PubMed  Google Scholar 

  • Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z et al. (2007). JARID1B is a histone H3 lysine 4 demethylase upregulated in prostate cancer. Proc Natl Acad Sci USA 104: 19226–19231.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N et al. (2005). The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 24: 5471–5481.

    CAS  PubMed  Google Scholar 

  • Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. (2011). Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43: 309–315.

    CAS  PubMed  Google Scholar 

  • Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M et al. (2000). Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 60: 4735–4739.

    CAS  PubMed  Google Scholar 

  • Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A et al. (2011). Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117: 2451–2459.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C et al. (2007). Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67: 6400–6408.

    CAS  PubMed  Google Scholar 

  • Yuge M, Nagai H, Uchida T, Murate T, Hayashi Y, Hotta T et al. (2000). HSNF5/INI1 gene mutations in lymphoid malignancy. Cancer Genet Cytogenet 122: 37–42.

    CAS  PubMed  Google Scholar 

  • Zeng J, Ge Z, Wang L, Li Q, Wang N, Bjorkholm M et al. (2010). The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 138: 981–992.

    CAS  PubMed  Google Scholar 

  • Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K et al. (2005). Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 94: 11–16.

    CAS  PubMed  Google Scholar 

  • Zhu P, Zhou W, Wang J, Puc J, Ohgi KA, Erdjument-Bromage H et al. (2007). A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol Cell 27: 609–621.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM et al. (2011). BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 477: 179–184.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu WG, Lakshmanan RR, Beal MD, Otterson GA . (2001). DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327–1333.

    CAS  PubMed  Google Scholar 

  • Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T et al. (2007). Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 67: 9047–9054.

    CAS  PubMed  Google Scholar 

  • Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524–528.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Carcinogenesis, Centre for Biomedical Genetics and Cancer Genomics Centre, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    E-J Geutjes, P K Bajpe & R Bernards

Authors
  1. E-J Geutjes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P K Bajpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Bernards
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Bernards.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geutjes, EJ., Bajpe, P. & Bernards, R. Targeting the epigenome for treatment of cancer. Oncogene 31, 3827–3844 (2012). https://doi.org/10.1038/onc.2011.552

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.552

Keywords

This article is cited by

Search

Advanced search

Quick links